Literature DB >> 10583383

Enovin, a member of the glial cell-line-derived neurotrophic factor (GDNF) family with growth promoting activity on neuronal cells. Existence and tissue-specific expression of different splice variants.

S Masure1, H Geerts, M Cik, E Hoefnagel, G Van Den Kieboom, A Tuytelaars, S Harris, A S Lesage, J E Leysen, L Van Der Helm, P Verhasselt, J Yon, R D Gordon.   

Abstract

Glial cell-line-derived neurotrophic factor (GDNF), neurturin and persephin are neurotrophic factors involved in neuroneal differentiation, development and maintenance. They act on different types of neuroneal cells and signal through a receptor complex composed of a specific ligand-binding subunit of the GDNF family receptor alpha (GFRalpha) family together with a common signaling partner, the cRET protein tyrosine kinase. We describe the molecular cloning, expression, chromosomal localization and functional characterization of enovin, a fourth GDNF family member almost identical to the recently described artemin. We show the occurence in most tissues of several differently spliced mRNA variants for enovin, of which only two are able to translate into functional enovin protein. Some tissues seem to express only nonfunctional transcripts. These observations may underlie a complex transcriptional regulation pattern. Enovin mRNA expression is detectable in all adult and fetal human tissues examined, but expression levels are highest in peripheral tissues including prostate, placenta, pancreas, heart and kidney. This tissue distribution pattern is in accordance with that of GFRalpha-3, which here is shown to be the preferred ligand-binding receptor for enovin (Kd = 3.1 nM). The human enovin gene is localized on chromosome 1, region p31.3-p32. In vitro, enovin stimulates neurite outgrowth and counteracts taxol-induced neurotoxicity in staurosporine-differentiated SH-SY5Y human neuroblastoma cells. The peripheral expression pattern of enovin and its receptor together with its effects on neuroneal cells suggest that enovin might be useful for the treatment of neurodegenerative diseases in general and peripheral neuropathies in particular.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10583383     DOI: 10.1046/j.1432-1327.1999.00925.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  6 in total

1.  Investigating the Role of Artemin Glycosylation.

Authors:  Qiu Danwen; Christian Code; Chao Quan; Bang-Jin Gong; Joseph Arndt; Blake Pepinsky; Kasper D Rand; Damian Houde
Journal:  Pharm Res       Date:  2016-02-23       Impact factor: 4.200

2.  Quantitative analysis of receptor tyrosine kinase-effector coupling at functionally relevant stimulus levels.

Authors:  Simin Li; Devayani Bhave; Jennifer M Chow; Thomas V Riera; Sandra Schlee; Simone Rauch; Mariya Atanasova; Richard L Cate; Adrian Whitty
Journal:  J Biol Chem       Date:  2015-01-29       Impact factor: 5.157

Review 3.  Targeting neurotrophic factors: Novel approaches to musculoskeletal pain.

Authors:  Anne-Marie Malfait; Rachel E Miller; Joel A Block
Journal:  Pharmacol Ther       Date:  2020-04-18       Impact factor: 12.310

4.  Acupuncture promotes functional recovery after cerebral hemorrhage by upregulating neurotrophic factor expression.

Authors:  Dan Li; Qiu-Xin Chen; Wei Zou; Xiao-Wei Sun; Xue-Ping Yu; Xiao-Hong Dai; Wei Teng
Journal:  Neural Regen Res       Date:  2020-08       Impact factor: 5.135

5.  An 18 gene expression-based score classifier predicts the clinical outcome in stage 4 neuroblastoma.

Authors:  Daniela Formicola; Giuseppe Petrosino; Vito Alessandro Lasorsa; Piero Pignataro; Flora Cimmino; Simona Vetrella; Luca Longo; Gian Paolo Tonini; André Oberthuer; Achille Iolascon; Matthias Fischer; Mario Capasso
Journal:  J Transl Med       Date:  2016-05-17       Impact factor: 5.531

Review 6.  The GDNF Family: A Role in Cancer?

Authors:  Graeme C Fielder; Teresa Wen-Shan Yang; Mahalakshmi Razdan; Yan Li; Jun Lu; Jo K Perry; Peter E Lobie; Dong-Xu Liu
Journal:  Neoplasia       Date:  2017-12-12       Impact factor: 5.715

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.